-
50 Years of Hematopoietic Stem Cell Transplantation: Xiaojun Huang on China’s Transformative Journey
Tracing the Origins Breaking Through Barriers: Milestones in Global Transplantation Technology In 1939, the first bone marrow transplant in human history was performed on a patient suffering from aplastic anemia…
-
Advancing AML Treatment in Asia: Insights from Professor Jianxiang Wang
We are thrilled to share an exclusive presentation by Professor Jianxiang Wang from the Institute of Hematology, Chinese Academy of Medical Sciences. In this engaging session, Professor Wang delves into the groundbreaking findings of the Phase 3 Commodore study, recently published in Leukemia. This study provides critical new evidence on the efficacy of gilteritinib, a…
-
Transforming Cancer Care: Insights from Professor Jun Zhou
Professor Jun Zhou from Shanghai GoBroad Cancer Hospital and China Pharmaceutical University discusses the pivotal findings of the CheckMate 649 study. This landmark trial has redefined the first-line treatment for advanced gastric cancer, showcasing the power of immunotherapy combined with chemotherapy.
-
Prof. Jie Wang on Integrating Targeted Therapy, Immunotherapy, and ADCs in Lung Cancer Management | Tianfu Oncology Conference
At the recent 7th Tianfu Oncology Conference, Professor Jie Wang from the Cancer Hospital, Chinese Academy of Medical Sciences, delivered a keynote presentation titled “Integrative Strategies in Lung Cancer: Targeted Therapy, Immunotherapy, and ADC Management.”
-
ADC Research Led by Sun Yat-sen University Cancer Center May Influence Future Treatment Guidelines
With advances in technology and growing clinical experience, China’s development of antibody-drug conjugates (ADCs) has evolved from following international trends to driving innovation independently. A recent example is the phase I clinical trial of YL201—the world’s first B7-H3-targeted ADC for advanced solid tumors—led by Professors Li Zhang and Hongyun Zhao from Sun Yat-sen University Cancer…
-
Omission of surgery in early breast cancer: Are we ready for a paradigm shift?
In a recent ESSO Research Academy survey led by Carmela Caballero and co-authored by Prof. Isabel T. Rubio, Prof. Evandro de Azambuja, and Prof. Stuart A. McIntosh, both clinicians and…
-
Advancing precision oncology with metabolomics and machine learning
A new study led by Dr. Rafael Nambo Venegas and colleagues, published in Metabolomics (Feb 2025), presents a high-accuracy predictive model for forecasting response to neoadjuvant therapy in breast cancer…
-
Risk-based breast cancer screening: A shift toward personalized prevention
In a recent study published in December 2024, Professor Isabel Rubio and her colleagues critically examined the limitations of current age-based breast cancer screening programs, which remain standard in most…
Connecting Medical Expertise through Media